Physician profile
John Yule Tsou
NPI 1750348983
$1,428.07
in general payments reported to CMS, 2019-2025
24 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.25 · 2020: $120 · 2021: $354 · 2022: $304 · 2023: $177 · 2024: $275 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $574.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $198.10 | 2020-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $189.20 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $133.40 | 2019-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $102.70 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $95.80 | 2020-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $88.30 | 2021-2024 | Farxiga |
| Abbott Laboratories | $84.98 | 2021-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $83.77 | 2022-2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $60.31 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Ibsa Pharma INC. | $52.46 | 2020-2024 | Tirosint, Licart |
| Dexcom, INC. | $47.96 | 2021-2024 | Dexcom G6 Transmitter |
| Ucb, INC. | $39.06 | 2022-2023 | Briviact |
| Astellas Pharma US INC | $34.16 | 2022 | |
| Sk Life Science, INC. | $33.51 | 2023-2024 | |
| Ultragenyx Pharmaceutical INC. | $25.25 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23.29 | 2022 | |
| Lundbeck LLC | $20.80 | 2023 | Rexulti |
| Rgh Enterprises LLC | $19.29 | 2024 | |
| Glaxosmithkline, LLC. | $18.90 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.84 | 2019 | |
| Antares Pharma, INC. | $14.89 | 2020 | |
| Avanir Pharmaceuticals, INC. | $14.76 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.54 | 2023 | Adthyza |
| Amneal Pharmaceuticals LLC | $13.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tsou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.